Aerska, an Ireland-based biotech developing RNA treatments for central nervous system disease, has appointed Laura Sepp-Lorenzino to its scientific advisory board as the company advances its antibody-oligonucleotide conjugate platform and a pipeline of RNA therapeutics. Dr Sepp-Lorenzino brings more than 30 years of experience in developing complex genetic medicines from early discovery through late-stage clinical development.
She was previously chief scientific officer of Intellia Therapeutics Inc, playing a lead role in advancing its CRISPR-based pipeline. Prior to Intellia, she led nucleic acid therapies at Vertex Pharmaceuticals Inc, and has also held leadership roles at Alnylam Pharmaceuticals Inc, where she led hepatic infectious disease programmes. Dr Sepp-Lorenzino, with a PhD in biochemistry from New York University, US, holds several board positions including at Asklepios Biopharmaceutical, and is President Elect of the Oligonucleotide Therapeutics Society, US.
Aerska announced the appointment on 17 September 2026.
Copyright 2026 Evernow Publishing Ltd